Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults

Jorge Kizer, David Benkeser, Alice M. Arnold, Luc Djousse, Susan J. Zieman, Kenneth J. Mukamal, Russell P. Tracy, Christos S. Mantzoros, David S. Siscovick, John S. Gottdiener, Joachim H. Ix

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Context: Adiponectin is atheroprotective in the laboratory, but prospective studies have shown opposite associations with cardiovascular disease (CVD) in healthy middle-aged populations (protective) and older cohorts (adverse). Whether this relates to different proportions of high-molecular-weight (HMW) adiponectin is unknown. Objective: The aim of the study was to test the hypothesis that total adiponectin is directly associated, but HMW adiponectin is inversely related, with CVD in older adults. Design, Setting, and Participants: We evaluated 3290 participants free of prevalent CVD in a longitudinal cohort study of U.S. adults aged 65 yr and older. Main Outcome Measures: We measured incident CVD (n = 1291), comprising coronary heart disease and ischemic stroke. Results: Total and HMW adiponectin were tightly correlated (r = 0.94). Cubic splines adjusted for potential confounders revealed that the associations of total and HMW adiponectin with CVD were U-shaped, with inflection points of 20 and 10 mg/liter, respectively. After controlling for potential confounding, levels of total and HMW adiponectin below these cutpoints tended to be inversely associated with incident CVD, driven by their significant or near-significant relations with coronary heart disease [hazard ratio (HR), 0.85 per SD increase; 95% confidence interval (CI), 0.75-96; and HR, 0.87; 95% CI, 0.75-1.01, respectively]. These associations were abrogated by additional inclusion of putative metabolic intermediates. Above these cutpoints, however, both total and HMW adiponectin were significantly directly associated with CVD after adjustment for confounders and, particularly, mediators (HR, 1.20 per SD increase; 95% CI, 1.06-1.35; and HR, 1.12; 95% CI, 1.02-1.24, respectively). Conclusion: In community-living elders, total and HMW adiponectin showed similar U-shaped relationships with CVD. The inverse relation in the lower range, but not the direct association at the higher end, disappeared after inclusion of putative intermediates, suggesting that high levels may reflect adverse processes separate from adiponectin's beneficial glycometabolic properties.

Original languageEnglish (US)
Pages (from-to)255-263
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number1
DOIs
StatePublished - Jan 2013
Externally publishedYes

Fingerprint

Adiponectin
Coronary Disease
Molecular Weight
Molecular weight
Stroke
Cardiovascular Diseases
Hazards
Confidence Intervals
Splines
Longitudinal Studies
Cohort Studies
Outcome Assessment (Health Care)
Prospective Studies

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. / Kizer, Jorge; Benkeser, David; Arnold, Alice M.; Djousse, Luc; Zieman, Susan J.; Mukamal, Kenneth J.; Tracy, Russell P.; Mantzoros, Christos S.; Siscovick, David S.; Gottdiener, John S.; Ix, Joachim H.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 1, 01.2013, p. 255-263.

Research output: Contribution to journalArticle

Kizer, J, Benkeser, D, Arnold, AM, Djousse, L, Zieman, SJ, Mukamal, KJ, Tracy, RP, Mantzoros, CS, Siscovick, DS, Gottdiener, JS & Ix, JH 2013, 'Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults', Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 1, pp. 255-263. https://doi.org/10.1210/jc.2012-2103
Kizer, Jorge ; Benkeser, David ; Arnold, Alice M. ; Djousse, Luc ; Zieman, Susan J. ; Mukamal, Kenneth J. ; Tracy, Russell P. ; Mantzoros, Christos S. ; Siscovick, David S. ; Gottdiener, John S. ; Ix, Joachim H. / Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults. In: Journal of Clinical Endocrinology and Metabolism. 2013 ; Vol. 98, No. 1. pp. 255-263.
@article{6cbc1b9480684937a020d7a8857052f0,
title = "Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults",
abstract = "Context: Adiponectin is atheroprotective in the laboratory, but prospective studies have shown opposite associations with cardiovascular disease (CVD) in healthy middle-aged populations (protective) and older cohorts (adverse). Whether this relates to different proportions of high-molecular-weight (HMW) adiponectin is unknown. Objective: The aim of the study was to test the hypothesis that total adiponectin is directly associated, but HMW adiponectin is inversely related, with CVD in older adults. Design, Setting, and Participants: We evaluated 3290 participants free of prevalent CVD in a longitudinal cohort study of U.S. adults aged 65 yr and older. Main Outcome Measures: We measured incident CVD (n = 1291), comprising coronary heart disease and ischemic stroke. Results: Total and HMW adiponectin were tightly correlated (r = 0.94). Cubic splines adjusted for potential confounders revealed that the associations of total and HMW adiponectin with CVD were U-shaped, with inflection points of 20 and 10 mg/liter, respectively. After controlling for potential confounding, levels of total and HMW adiponectin below these cutpoints tended to be inversely associated with incident CVD, driven by their significant or near-significant relations with coronary heart disease [hazard ratio (HR), 0.85 per SD increase; 95{\%} confidence interval (CI), 0.75-96; and HR, 0.87; 95{\%} CI, 0.75-1.01, respectively]. These associations were abrogated by additional inclusion of putative metabolic intermediates. Above these cutpoints, however, both total and HMW adiponectin were significantly directly associated with CVD after adjustment for confounders and, particularly, mediators (HR, 1.20 per SD increase; 95{\%} CI, 1.06-1.35; and HR, 1.12; 95{\%} CI, 1.02-1.24, respectively). Conclusion: In community-living elders, total and HMW adiponectin showed similar U-shaped relationships with CVD. The inverse relation in the lower range, but not the direct association at the higher end, disappeared after inclusion of putative intermediates, suggesting that high levels may reflect adverse processes separate from adiponectin's beneficial glycometabolic properties.",
author = "Jorge Kizer and David Benkeser and Arnold, {Alice M.} and Luc Djousse and Zieman, {Susan J.} and Mukamal, {Kenneth J.} and Tracy, {Russell P.} and Mantzoros, {Christos S.} and Siscovick, {David S.} and Gottdiener, {John S.} and Ix, {Joachim H.}",
year = "2013",
month = "1",
doi = "10.1210/jc.2012-2103",
language = "English (US)",
volume = "98",
pages = "255--263",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults

AU - Kizer, Jorge

AU - Benkeser, David

AU - Arnold, Alice M.

AU - Djousse, Luc

AU - Zieman, Susan J.

AU - Mukamal, Kenneth J.

AU - Tracy, Russell P.

AU - Mantzoros, Christos S.

AU - Siscovick, David S.

AU - Gottdiener, John S.

AU - Ix, Joachim H.

PY - 2013/1

Y1 - 2013/1

N2 - Context: Adiponectin is atheroprotective in the laboratory, but prospective studies have shown opposite associations with cardiovascular disease (CVD) in healthy middle-aged populations (protective) and older cohorts (adverse). Whether this relates to different proportions of high-molecular-weight (HMW) adiponectin is unknown. Objective: The aim of the study was to test the hypothesis that total adiponectin is directly associated, but HMW adiponectin is inversely related, with CVD in older adults. Design, Setting, and Participants: We evaluated 3290 participants free of prevalent CVD in a longitudinal cohort study of U.S. adults aged 65 yr and older. Main Outcome Measures: We measured incident CVD (n = 1291), comprising coronary heart disease and ischemic stroke. Results: Total and HMW adiponectin were tightly correlated (r = 0.94). Cubic splines adjusted for potential confounders revealed that the associations of total and HMW adiponectin with CVD were U-shaped, with inflection points of 20 and 10 mg/liter, respectively. After controlling for potential confounding, levels of total and HMW adiponectin below these cutpoints tended to be inversely associated with incident CVD, driven by their significant or near-significant relations with coronary heart disease [hazard ratio (HR), 0.85 per SD increase; 95% confidence interval (CI), 0.75-96; and HR, 0.87; 95% CI, 0.75-1.01, respectively]. These associations were abrogated by additional inclusion of putative metabolic intermediates. Above these cutpoints, however, both total and HMW adiponectin were significantly directly associated with CVD after adjustment for confounders and, particularly, mediators (HR, 1.20 per SD increase; 95% CI, 1.06-1.35; and HR, 1.12; 95% CI, 1.02-1.24, respectively). Conclusion: In community-living elders, total and HMW adiponectin showed similar U-shaped relationships with CVD. The inverse relation in the lower range, but not the direct association at the higher end, disappeared after inclusion of putative intermediates, suggesting that high levels may reflect adverse processes separate from adiponectin's beneficial glycometabolic properties.

AB - Context: Adiponectin is atheroprotective in the laboratory, but prospective studies have shown opposite associations with cardiovascular disease (CVD) in healthy middle-aged populations (protective) and older cohorts (adverse). Whether this relates to different proportions of high-molecular-weight (HMW) adiponectin is unknown. Objective: The aim of the study was to test the hypothesis that total adiponectin is directly associated, but HMW adiponectin is inversely related, with CVD in older adults. Design, Setting, and Participants: We evaluated 3290 participants free of prevalent CVD in a longitudinal cohort study of U.S. adults aged 65 yr and older. Main Outcome Measures: We measured incident CVD (n = 1291), comprising coronary heart disease and ischemic stroke. Results: Total and HMW adiponectin were tightly correlated (r = 0.94). Cubic splines adjusted for potential confounders revealed that the associations of total and HMW adiponectin with CVD were U-shaped, with inflection points of 20 and 10 mg/liter, respectively. After controlling for potential confounding, levels of total and HMW adiponectin below these cutpoints tended to be inversely associated with incident CVD, driven by their significant or near-significant relations with coronary heart disease [hazard ratio (HR), 0.85 per SD increase; 95% confidence interval (CI), 0.75-96; and HR, 0.87; 95% CI, 0.75-1.01, respectively]. These associations were abrogated by additional inclusion of putative metabolic intermediates. Above these cutpoints, however, both total and HMW adiponectin were significantly directly associated with CVD after adjustment for confounders and, particularly, mediators (HR, 1.20 per SD increase; 95% CI, 1.06-1.35; and HR, 1.12; 95% CI, 1.02-1.24, respectively). Conclusion: In community-living elders, total and HMW adiponectin showed similar U-shaped relationships with CVD. The inverse relation in the lower range, but not the direct association at the higher end, disappeared after inclusion of putative intermediates, suggesting that high levels may reflect adverse processes separate from adiponectin's beneficial glycometabolic properties.

UR - http://www.scopus.com/inward/record.url?scp=84872060008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872060008&partnerID=8YFLogxK

U2 - 10.1210/jc.2012-2103

DO - 10.1210/jc.2012-2103

M3 - Article

C2 - 23162097

AN - SCOPUS:84872060008

VL - 98

SP - 255

EP - 263

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 1

ER -